Evaluating Lip Repositioning for the Treatment of Excess Gingival Display With and Without Pretreatment With Botox
NCT ID: NCT04030767
Last Updated: 2019-07-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
22 participants
INTERVENTIONAL
2019-09-20
2022-09-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Botox injections have been suggested as a possible treatment for cases with relapse Botox acts by blocking muscular activity, however, Botulinum toxin technique has a transitory effect (6-7 months). . By combining Botox as a pretreatment and lip repositioning surgery, Botox injections maybe a useful adjunct in improving and stabilizing the results of achieved, by paralyzing the muscles during the healing period.
There are no studies, to the investigator's knowledge, exploring the use of botox combined with lip repositioning to decrease muscle pull and therefore decrease the relapse.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Botox Before Modified Lip Repositioning Repositioning Only in Relapse of the Excessive Gingival Display Within One Year
NCT06148961
Effect of Botox Injection in Anterior Belly of Digastric on Skeletal Relapse Following Mandibular Advancement Surgery
NCT05573581
Satisfaction Of Adult Patients With Gummy Smile Treated By Botulinum Toxin A Injection
NCT03186547
Assessment of Botulinum Toxin Injection for Treatment of Temporomandibular Joint Dislocation
NCT05863286
Botulinum Toxin Injection in Reducing Lip Scar Following Cleft Lip Repair
NCT05559281
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Many studies have stated the main causes of excessive gingival display, presenting the most important factors which may lead to having a gummy Smile. The study of Roe described that lip length and the upper lip mobility rate are the main contributing factors. The previous research stated that the exposure of teeth and gingiva depends on the integrated effects of a number of variables (increased muscle capacity, vertical maxillary excess, greater inter-labial gap at resting position, and the amount of over-jet and over-bite). Pausch \& Katsoulis mentioned that abnormal gingival and maxillary anterior teeth display may take place due to numerous anatomic or functional factors, either hereditary or inborn. A narrow upper lip, an irregular eruption of teeth, excessive protuberance or vertical maxillary growth, and hypermobility of the maxillary lip and elevator muscle are common reasons for a gummy Smile. In fact, several contributing factors are affecting individuals to have a gummy Smile. Sometimes one of them is presented, although in some cases more than only one cause can be seen. Correct diagnosis of the reason leads to a proper treatment plan.
Excessive gingival display can be managed by a variety of procedures. These procedures include surgical and non-surgical methods The underlying cause of excessive gingival display or gummy Smile has the main effect on the type of procedure that will be performed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Blinding of the participants is not applicable. Blinding of the operator is not applicable. Outcome assessor (primary and secondary outcomes) \& biostatistician will be blinded.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
lip repositioning technique with Botox injection.
Botulinum toxin produces partial chemical denervation of the muscle resulting in localized reduction in muscle activity (Binder et al., 1998).
Therefore, the technique is a useful adjunct in the esthetic improvement of the smile and provides better results when combined with resective gingival surgery(Pedron \& Mangano, 2018).
Botox Injectable Product
Botulinum toxin produces partial chemical denervation of the muscle resulting in localized reduction in muscle activity
lip repositioning technique.
Lip repositioning aims to limit the retraction of elevator smile muscles. Lip repositioning results in a shallow vestibuler restricting of the muscle pull; Thereby limiting the gingival display during smiling.(Makkiah, 2017) It is a less invasive, viable substitute for patients, has fewer post-operative complications and provides a faster recovery compared to orthognathic surgery(Grover, Gupta, \& Luthra, 2014).
Botox Injectable Product
Botulinum toxin produces partial chemical denervation of the muscle resulting in localized reduction in muscle activity
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Botox Injectable Product
Botulinum toxin produces partial chemical denervation of the muscle resulting in localized reduction in muscle activity
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Adults \>18 years.
3. Non-smokers.
4. Patients with healthy systemic condition
5. Normal clinical crown dimensions.
6. Good oral hygiene.
Exclusion Criteria
2. Pregnant or lactating women.
3. Patients with inflamed gingiva or gingival enlargement.
4. Inflammation or infection at the site of injection.
5. Patients with allergy to botulinum toxin, lactose, and albumin.
6. Concurrent use of aminoglycoside antibiotic that enhances the action of the toxin. (Jaspers, Pijpe, \& Jansma, 2011)
7. \< 3 mm attached gingivae that might create difficulties in flap design, stabilization and suturing.
8. Patients using anticholinesterase or other agents interfering with neuromuscular transmission
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ola mostafa ghoniem
Principal Investigator
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2261986
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.